← Back to Search

Other

Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients

Phase 1 & 2
Waitlist Available
Research Sponsored by JW Pharmaceutical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3rd cycle (each cycle = 28 days), cycle 1 day 1: pre, 0.5hr, 1hr, 2hr, 3hr, 4hr, 5hr, 8hr, and 24hr after the start of infusion in part a and at cycle 1 day 1: pre, 2hr, 4hr, 8hr, and 24hr after the start of infusion in part b.
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug to see if it is safe and effective in people with relapsed or refractory AML. The primary objective is to assess the efficacy of the drug in combination with another drug, cytarabine.

Eligible Conditions
  • Acute Myeloid Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3rd cycle (each cycle = 28 days), cycle 1 day 1: pre, 0.5hr, 1hr, 2hr, 3hr, 4hr, 5hr, 8hr, and 24hr after the start of infusion in part a and at cycle 1 day 1: pre, 2hr, 4hr, 8hr, and 24hr after the start of infusion in part b.
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3rd cycle (each cycle = 28 days), cycle 1 day 1: pre, 0.5hr, 1hr, 2hr, 3hr, 4hr, 5hr, 8hr, and 24hr after the start of infusion in part a and at cycle 1 day 1: pre, 2hr, 4hr, 8hr, and 24hr after the start of infusion in part b. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Recommended Phase 2 dose
Secondary study objectives
AUC0-t as a Pharmacokinetic (PK) assessments for CWP232291
AUC0-τ as a Pharmacokinetic (PK) assessments for CWP232291
AUC0-∞ as a Pharmacokinetic (PK) assessments for CWP232291
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: CWP232291 in combination with cytarabine (ara-C)Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CWP232291
2011
Completed Phase 1
~70

Find a Location

Who is running the clinical trial?

JW PharmaceuticalLead Sponsor
76 Previous Clinical Trials
43,171 Total Patients Enrolled
~5 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top